[go: up one dir, main page]

PT2549995T - Utilização de anatabina para tratar inflamação e métodos de sintetizar a anatabina - Google Patents

Utilização de anatabina para tratar inflamação e métodos de sintetizar a anatabina

Info

Publication number
PT2549995T
PT2549995T PT117148809T PT11714880T PT2549995T PT 2549995 T PT2549995 T PT 2549995T PT 117148809 T PT117148809 T PT 117148809T PT 11714880 T PT11714880 T PT 11714880T PT 2549995 T PT2549995 T PT 2549995T
Authority
PT
Portugal
Prior art keywords
anatabine
methods
synthesizing
treat inflammation
inflammation
Prior art date
Application number
PT117148809T
Other languages
English (en)
Original Assignee
Rock Creek Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/729,346 external-priority patent/US8207346B2/en
Application filed by Rock Creek Pharmaceuticals Inc filed Critical Rock Creek Pharmaceuticals Inc
Publication of PT2549995T publication Critical patent/PT2549995T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT117148809T 2010-03-23 2011-03-23 Utilização de anatabina para tratar inflamação e métodos de sintetizar a anatabina PT2549995T (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12/729,346 US8207346B2 (en) 2010-03-23 2010-03-23 Methods of synthesizing anatabine
US38381110P 2010-09-17 2010-09-17
US38444710P 2010-09-20 2010-09-20
US201161439483P 2011-02-04 2011-02-04
US201161439473P 2011-02-04 2011-02-04

Publications (1)

Publication Number Publication Date
PT2549995T true PT2549995T (pt) 2021-07-29

Family

ID=44201080

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117148809T PT2549995T (pt) 2010-03-23 2011-03-23 Utilização de anatabina para tratar inflamação e métodos de sintetizar a anatabina

Country Status (8)

Country Link
EP (4) EP2549995B1 (pt)
AU (5) AU2011232478A1 (pt)
CA (1) CA2794097C (pt)
DK (1) DK2549995T3 (pt)
ES (1) ES2869851T3 (pt)
PL (2) PL2549995T3 (pt)
PT (1) PT2549995T (pt)
WO (1) WO2011119722A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012302257A1 (en) * 2011-08-29 2014-03-13 Rcp Development, Inc. Products for anti-inflammation support
EP2793026A1 (en) 2013-04-18 2014-10-22 Centre National de la Recherche Scientifique (CNRS) New method for monitoring cancer and/or inflammatory reaction based on relb phosphorylation
PL3898607T3 (pl) 2018-12-17 2024-03-18 Philip Morris Products S.A. Glutaran 3-(1,2,3,6-tetrahydropirydyn-2-ylo)pirydyny lub jego farmaceutycznie dopuszczalny solwat
JP2023529411A (ja) 2020-06-15 2023-07-10 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム アナタビン粉末組成物
IL300741A (en) 2020-09-03 2023-04-01 Philip Morris Products Sa Active powder compositions with low hygroscopicity
US20230346696A1 (en) 2020-09-03 2023-11-02 Philip Morris Products S.A. Spray dried low hygroscopicity active powder compositions
PL4208151T3 (pl) 2020-09-03 2024-11-04 Philip Morris Products S.A. Liofilizowane aktywne kompozycje proszku o niskiej higroskopijności
CN113880802A (zh) * 2021-11-09 2022-01-04 深圳萨特瓦生物科技有限公司 酒石酸-尼古丁盐及其制备方法与应用、无水酒石酸晶体的制备方法
US20250043298A1 (en) 2021-12-20 2025-02-06 Philip Morris Products S.A. Increasing anatabine in tobacco leaf by regulating methyl putrescine oxidase
CN115594662A (zh) * 2022-10-19 2023-01-13 昆明理工大学(Cn) 一种(s)-烟碱的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3901248A (en) 1970-07-22 1975-08-26 Leo Ab Chewable smoking substitute composition
DE4002784C1 (pt) 1990-01-31 1991-04-18 B.A.T. Cigarettenfabriken Gmbh, 2000 Hamburg, De
US5065775A (en) 1990-02-23 1991-11-19 R. J. Reynolds Tobacco Company Tobacco processing
US5276043A (en) * 1992-04-10 1994-01-04 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5942244A (en) 1997-07-31 1999-08-24 Farmo-Nat Ltd. Local oral herbal slow release tablets
AU770309B2 (en) * 1998-06-05 2004-02-19 Regent Court Technologies Monoamine oxidase (MAO) inhibitors and uses thereof
JP2003536075A (ja) * 2000-06-08 2003-12-02 ボード・オブ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム C反応性タンパク質誘導性炎症のインヒビター
CA2341952A1 (en) * 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
EP2386862A1 (en) 2002-10-09 2011-11-16 DMI Biosciences, Inc. Methods and kits for diagnosing appendicitis
EP2927693A1 (en) 2004-10-06 2015-10-07 The Brigham and Women's Hospital Relevance of achieved levels of markers of systemic inflammation following treatment
MX2008014828A (es) * 2006-05-22 2009-02-06 Combinatorx Inc Metodos y composiciones para el tratamiento de enfermedades o condiciones asociadas con niveles incrementados de proteina c-reactiva, interleucina-6 o interferon-gamma.
US8841329B2 (en) * 2008-09-11 2014-09-23 Dignity Health Nicotinic attenuation of CNS inflammation and autoimmunity
US8151804B2 (en) 2008-12-23 2012-04-10 Williams Jonnie R Tobacco curing method

Also Published As

Publication number Publication date
AU2017201593A1 (en) 2017-03-30
PL3871674T3 (pl) 2025-04-14
EP2549995A2 (en) 2013-01-30
CA2794097A1 (en) 2011-09-29
WO2011119722A2 (en) 2011-09-29
EP3524245A1 (en) 2019-08-14
AU2017201593C1 (en) 2019-06-27
PL2549995T3 (pl) 2021-09-27
EP3871674B1 (en) 2024-12-25
AU2019200103A1 (en) 2019-01-31
EP3871674C0 (en) 2024-12-25
AU2019200102A1 (en) 2019-01-31
AU2020257090B2 (en) 2021-12-02
WO2011119722A3 (en) 2011-12-29
CA2794097C (en) 2016-08-09
ES2869851T3 (es) 2021-10-26
AU2019200103B2 (en) 2020-07-30
EP3524246A1 (en) 2019-08-14
EP3871674A1 (en) 2021-09-01
AU2011232478A1 (en) 2015-11-19
EP2549995B1 (en) 2021-04-21
DK2549995T3 (da) 2021-05-25
AU2020257090A1 (en) 2020-11-19
AU2017201593B2 (en) 2019-02-28
AU2019200102B2 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
IL267014A (en) Preparations and methods for the treatment of autoimmune diseases and other diseases
PT2549995T (pt) Utilização de anatabina para tratar inflamação e métodos de sintetizar a anatabina
EP2603202A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF TAUOPATHIES
EP2435426B8 (en) BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE
SG10202009963PA (en) Melanin modification compositions and methods of use
EP2448581A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS OF USE THEREOF
IL221476A0 (en) Methods and compositions to treat hemorrhagic conditions of the brain
EP2831001A4 (en) COMPOSITION FOR THE TREATMENT OF WATER AND METHOD FOR USE
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
EP2521549A4 (en) THERAPEUTIC COMPOUNDS AND ASSOCIATED METHODS OF USE
PL2588593T3 (pl) Kompozycje i sposoby stymulowania MAGP-1 dla poprawy wyglądu skóry
EP2574172A4 (en) MATERIALS AND METHOD FOR TREATING INFLAMMATION
GB201302653D0 (en) Pharmaceutical compositions and methods of treatment
AP3480A (en) Phosphaplatins and their use for treatment of cancers
EP2480579A4 (en) METHODS OF TREATING INFLAMMATION
IL232135A0 (en) Therapeutic combinations and methods for treating melanoma
IL256026B (en) Treatment methods
IL229968A0 (en) Tetrazolyloxy derivatives and methods for their production
GB201115521D0 (en) Colorant-polyesters and methods of producing colorant-polyesters
PL2609156T3 (pl) Kompozycje zmniejszające opór przepływu i sposoby ich wytwarzania i zastosowanie
ZA201408057B (en) Compositions and methods for the treatment of moderate to severe pain
EP2672968A4 (en) ECONAZOL COMPOSITION AND TREATMENT PROCEDURE THEREWITH
SG11201504779YA (en) Methods and compositions relating to treatment of cancer
EP2563923A4 (en) COMPOSITIONS AND METHODS FOR REDUCING SCARS AND TREATING FIBROSIS
EP2649096A4 (en) HEMOGLOBIN COMPOSITIONS AND METHODS OF USE